ORIGINAL ARTICLE
Retrospective analysis of negative cytology results
correlated with a positive high-risk in the human
papillomavirus result and subsequent results
of patients over a period of three years
1
Lab Path Experts, Koziegłowy, Poland
2
Departament of Immunopathology and Molecular Biology, Medical University, Wrocław, Poland
Submission date: 2023-10-13
Acceptance date: 2024-01-09
Publication date: 2024-02-29
Corresponding author
Paweł Gerard Piotrowski
Paweł Gerard Piotrowski, MD Lab Path Experts Koziegłowy, Poland
Paweł Gerard Piotrowski, MD Lab Path Experts Koziegłowy, Poland
Pol J Pathol 2024;75(1):36-39
KEYWORDS
cervical cancerco-testingcytology testsHPVefficacyretrospective reviewhigh-risk HPVmRNA-based HPV testingfalse-negative cytologypreventive care
TOPICS
ABSTRACT
This research paper evaluates the efficacy of co-testing in precluding cervical cancer, with a particular focus on distinguishable outcomes of the human papillomavirus (HPV) vs. cytology tests.
A retrospective review of 5948 patients, who tested positive for high-risk HPV but showed negative cytologic findings, revealed that 15.006% tested positive in subsequent screenings.
A comparative analysis of various commercial HPV tests highlighted the precision of mRNA-based HPV testing by Aptima (Hologic) in reducing the likelihood of false-negative cytology.
The paper challenges the conviction that a negative cytology alone suffices advocating for a condensed testing interval in instances of positive HPV outcomes, thereby facilitating earlier intervention and optimal preventive care. These findings unveil an exigency for reconsidering preventive strategies based on test outcomes.
A retrospective review of 5948 patients, who tested positive for high-risk HPV but showed negative cytologic findings, revealed that 15.006% tested positive in subsequent screenings.
A comparative analysis of various commercial HPV tests highlighted the precision of mRNA-based HPV testing by Aptima (Hologic) in reducing the likelihood of false-negative cytology.
The paper challenges the conviction that a negative cytology alone suffices advocating for a condensed testing interval in instances of positive HPV outcomes, thereby facilitating earlier intervention and optimal preventive care. These findings unveil an exigency for reconsidering preventive strategies based on test outcomes.
REFERENCES (22)
1.
Bruni L, Albero G, Serrano B, et al. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Poland. Summary Report 10 March 2023.
2.
Baussano J, Bray F. Modelling cervical cancer elimination. Lancet Public Health 2019; 4: PE2-3.
3.
Forman D, de Martel C, Lacey CJ. Global burden of human papillomavirus and related diseases. Vaccine 2012; 30S: F12-23.
4.
Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890-907.
5.
Cuzick J, Clavel C, Petry KU. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119: 1095-1101.
6.
Gissmann L, Wolnik L, Ikenberg H, et al. Human papillomavirus type 6 and 11 sequences in genital and laryngeal papillomas and some cervical cancers. Proc Natl Acad Sci USA 1983; 80: 560-563.
7.
Zur Hausen H. Papillomaviruses in the causation of human cancers – a brief historical account. Virology 2009; 384: 260-265.
8.
Meisels A, Fortin R. Condylomatous lesions of the cervix and vagina.1. Cytologic patterns. Acta Cytol 1976; 20: 505-509.
9.
Gasparini R, Panatto D. Cervical cancer: from Hippocrates through Rigoni-Stern to zur Hausen. Vaccine 2008; 27: A4-5.
10.
Koliopoulos G, Nyaga VN, Santesso N, et al Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev 2017; 8: CD008587.
11.
Arbyn M, Ronco G, Anttila A, et al Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012; 30: F88-99.
12.
Melnikow J, Henderson JT, Burda BU, Senger CA, Durbin S, Weyrich MS. Screening for cervical cancer with high-risk human papillomavirus testing: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2018; 320: 687-705.
13.
Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol 2015; 136: 189-197.
14.
Xhaja A, Ahr A, Zeiser I, Ikenberg H. Two years of cytology and HPV co-testing in Germany: initial experience. Geburtshilfe Frauenheilkd 2022; 82: 1378-1386.
15.
Pankaj S, Kumari A, Kumari S, et al. Evaluation of sensitivity and specificity of Pap Smear, LBC and HPV in screening of cervical cancer. Indian J Gynecol Oncolog 2018; 16: 49.
17.
Wojciechowska U, Barańska K, Michałek I, Olasek P, Mikleska M, Didkowaska JA. Nowotwory złośliwe w Polsce 2020 roku. Biuletyn Krajowego Rejestru Nowotworów, Warszawa 2022.
18.
Dalstein V, Merlin S, Bali C, Saunier M, Dachez R, Ronsin C. Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus. J Virol Methods 2009; 156: 77-83.
19.
You J, Croyle JL, Nishimura A, Ozato K, Howley PM. Interaction of the bovine papillomavirus E2 protein with Brd4 tethers the viral DNA to host mitotic chromosomes. Cell 2004; 117: 349-360.
20.
McBride AA, McPhillips MG, Oliveira JG. Brd4: tethering, segregation and beyond. Trends Microbiol 2004; 12: 527-579.
21.
Pal A, Kundu R. Human papillomavirus E6 and E7: the cervical cancer hallmarks and targets for therapy. Front Microbiol 2020; 10: 3116.
22.
Informacja Ministra Zdrowia w sprawie włączenia do wykazu refundowanych leków szczepionki przeciw wirusowi brodawczaka ludzkiego (HPV) oraz zmian w e-Karcie Szczepień. ZPŚ.641.185.2021.JK.2, 29.10.2021 r.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
